Hepatic stellate cells: Partners in crime for liver metastases?

Hepatology

Volumn 54, Issue 2, 2011, Pages 707-713

  Kang, Ningling ^a   Gores, Gregory J ^a   Shah, Vijay H ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; API 2009; CYTOKINE; FRESOLIMUMAB; GROWTH FACTOR; IMATINIB; LY 2109761; LY 2157299; PLATELET DERIVED GROWTH FACTOR; SORAFENIB; SUNITINIB; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ANGIOGENESIS; CANCER CELL; CANCER GROWTH; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL TRANSDIFFERENTIATION; DRUG POTENCY; EXTRACELLULAR MATRIX; HUMAN; LIVER METASTASIS; MYOFIBROBLAST; NONHUMAN; PRIORITY JOURNAL; PROTEIN METABOLISM; REVIEW; SIGNAL TRANSDUCTION; STELLATE CELL; STROMA; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT;

ANIMALS; HEPATIC STELLATE CELLS; HUMANS; LIVER NEOPLASMS; TUMOR MICROENVIRONMENT;

EID: 79960727727     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.24384     Document Type: Review

References (57)

1. Vidal-Vanaclocha F. The prometastatic microenvironment of the liver. Cancer Microenviron 2008; 1: 113-129.
2. Ahmad SA, Berman RS, Ellis LM. Biology of colorectal liver metastases. Surg Oncol Clin N Am 2003; 12: 135-150.
3. Yang JD, Nakamura I, Roberts LR. The tumor microenvironment in hepatocellular carcinoma: current status and therapeutic targets. Semin Cancer Biol 2011; 21: 35-43.
4. Friedman SL. Mechanisms of disease: Mechanisms of hepatic fibrosis and therapeutic implications. Nat Clin Pract Gastroenterol Hepatol 2004; 1: 98-105.
5. Friedman SL. Mechanisms of hepatic fibrogenesis. Gastroenterology 2008; 134: 1655-1669.
6. Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer 2006; 6: 392-401.
7. Paget S. The distribution of secondary growths in cancer of the breast. Lancet 1889; 1: 99-101.
8. Paget S. The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev 1989; 8: 98-101.
9. Chambers AF, Groom AC, MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2002; 2: 563-572.
10. Ewing J, editor. Neoplastic Diseases. A Treatise on Tumors. Philadelphia, PA: W.B. Saunders Co.; 1928. pp. 77-89.
11. Luzzi KJ, MacDonald IC, Schmidt EE, Kerkvliet N, Morris VL, Chambers AF, et al. Multistep nature of metastatic inefficiency: dormancy of solitary cells after successful extravasation and limited survival of early micrometastases. Am J Pathol 1998; 153: 865-873.
12. Okabe H, Beppu T, Hayashi H, Horino K, Masuda T, Komori H, et al. Hepatic stellate cells may relate to progression of intrahepatic cholangiocarcinoma. Ann Surg Oncol 2009; 16: 2555-2564.
13. Amann T, Bataille F, Spruss T, Muhlbauer M, Gabele E, Scholmerich J, et al. Activated hepatic stellate cells promote tumorigenicity of hepatocellular carcinoma. Cancer Sci 2009; 100: 646-653.
14. Okabe H, Beppu T, Hayashi H, Ishiko T, Masuda T, Otao R, et al. Hepatic stellate cells accelerate the malignant behavior of cholangiocarcinoma cells. Ann Surg Oncol 2011; 18: 1175-1184.
15. Zhao W, Zhang L, Yin Z, Su W, Ren G, Zhou C, et al. Activated hepatic stellate cells promote hepatocellular carcinoma development in immunocompetent mice. Int J Cancer 2011; doi:10.1002/ijc.25920.
16. Mazzocca A, Coppari R, De Franco R, Cho JY, Libermann TA, Pinzani M, et al. A secreted form of ADAM9 promotes carcinoma invasion through tumor-stromal interactions. Cancer Res 2005; 65: 4728-4738.
17. Shimizu S, Yamada N, Sawada T, Ikeda K, Kawada N, Seki S, et al. In vivo and in vitro interactions between human colon carcinoma cells and hepatic stellate cells. Jpn J Cancer Res 2000; 91: 1285-1295.
18. Mikula M, Proell V, Fischer AN, Mikulits W. Activated hepatic stellate cells induce tumor progression of neoplastic hepatocytes in a TGF-beta dependent fashion. J Cell Physiol 2006; 209: 560-567.
19. Kang N, Yaqoob U, Geng Z, Bloch K, Liu C, Gomez T, et al. Focal adhesion assembly in myofibroblasts fosters a microenvironment that promotes tumor growth. Am J Pathol; 177: 1888-1900.
20. Kang N, Liu C, Kaibuchi K, Bloom G, Billadeau D, Shah V. IQGAP1 inhibits TGF-β1 mediated hepatic stellate cell activation in vitro and liver metastatic growth in vivo through effects on tumor microenvironment [Abstract]. Hepatology 2010; 52(suppl S1):400A.
21. Ju MJ, Qiu SJ, Fan J, Xiao YS, Gao Q, Zhou J, et al. Peritumoral activated hepatic stellate cells predict poor clinical outcome in hepatocellular carcinoma after curative resection. Am J Clin Pathol 2009; 131: 498-510.
22. Matsusue R, Kubo H, Hisamori S, Okoshi K, Takagi H, Hida K, et al. Hepatic stellate cells promote liver metastasis of colon cancer cells by the action of SDF-1/CXCR4 axis. Ann Surg Oncol 2009; 16: 2645-2653.
23. Theret N, Musso O, Turlin B, Lotrian D, Bioulac-Sage P, Campion JP, et al. Increased extracellular matrix remodeling is associated with tumor progression in human hepatocellular carcinomas. Hepatology 2001; 34: 82-88.
24. Musso O, Theret N, Campion JP, Turlin B, Milani S, Grappone C, et al. In situ detection of matrix metalloproteinase-2 (MMP2) and the metalloproteinase inhibitor TIMP2 transcripts in human primary hepatocellular carcinoma and in liver metastasis. J Hepatol 1997; 26: 593-605.
25. Theret N, Musso O, Campion JP, Turlin B, Loreal O, L'Helgoualc'h A, et al. Overexpression of matrix metalloproteinase-2 and tissue inhibitor of matrix metalloproteinase-2 in liver from patients with gastrointestinal adenocarcinoma and no detectable metastasis. Int J Cancer 1997; 74: 426-432.
26. Nagaprashantha LD, Vatsyayan R, Lelsani PC, Awasthi S, Singhal SS. The sensors and regulators of cell-matrix surveillance in anoikis resistance of tumors. Int J Cancer 2011; 128: 743-752.
27. Cox D, Brennan M, Moran N. Integrins as therapeutic targets: lessons and opportunities. Nat Rev Drug Discov 2010; 9: 804-820.
28. Hodkinson PS, Mackinnon AC, Sethi T. Extracellular matrix regulation of drug resistance in small-cell lung cancer. Int J Radiat Biol 2007; 83: 733-741.
29. Olive KP, Jacobetz MA, Davidson CJ, Gopinathan A, McIntyre D, Honess D, et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 2009; 324: 1457-1461.
30. Wirz W, Antoine M, Tag CG, Gressner AM, Korff T, Hellerbrand C, et al. Hepatic stellate cells display a functional vascular smooth muscle cell phenotype in a three-dimensional co-culture model with endothelial cells. Differentiation 2008; 76: 784-794.
31. Semela D, Das A, Langer D, Kang N, Leof E, Shah V. Platelet-derived growth factor signaling through ephrin-b2 regulates hepatic vascular structure and function. Gastroenterology 2008; 135: 671-679.
32. Torimura T, Sata M, Ueno T, Kin M, Tsuji R, Suzaku K, et al. Increased expression of vascular endothelial growth factor is associated with tumor progression in hepatocellular carcinoma. Hum Pathol 1998; 29: 986-991.
33. Torimura T, Ueno T, Kin M, Harada R, Taniguchi E, Nakamura T, et al. Overexpression of angiopoietin-1 and angiopoietin-2 in hepatocellular carcinoma. J Hepatol 2004; 40: 799-807.
34. Olaso E, Salado C, Egilegor E, Gutierrez V, Santisteban A, Sancho-Bru P, et al. Proangiogenic role of tumor-activated hepatic stellate cells in experimental melanoma metastasis. Hepatology 2003; 37: 674-685.
35. Taura K, De Minicis S, Seki E, Hatano E, Iwaisako K, Osterreicher CH, et al. Hepatic stellate cells secrete angiopoietin 1 that induces angiogenesis in liver fibrosis. Gastroenterology 2008; 135: 1729-1738.
36. Yaqoob U, Cao S, Geng Z, Shergill U, Jagavelu K, Shah V. Neuropilin-1 promotes fibronectin signaling in hepatic stellate cells that enhances tumor growth through effects on tumor microenvironment [Abstract]. Hepatology 2010; 52(suppl S1):345A.
37. Yu MC, Chen CH, Liang X, Wang L, Gandhi CR, Fung JJ, et al. Inhibition of T-cell responses by hepatic stellate cells via B7-H1-mediated T-cell apoptosis in mice. Hepatology 2004; 40: 1312-1321.
38. Chen CH, Kuo LM, Chang Y, Wu W, Goldbach C, Ross MA, et al. In vivo immune modulatory activity of hepatic stellate cells in mice. Hepatology 2006; 44: 1171-1181.
39. Yingling JM, Blanchard KL, Sawyer JS. Development of TGF-beta signalling inhibitors for cancer therapy. Nat Rev Drug Discov 2004; 3: 1011-1022.
40. Pinzani M, Marra F. Cytokine receptors and signaling in hepatic stellate cells. Semin Liver Dis 2001; 21: 397-416.
41. Pinzani M. PDGF and signal transduction in hepatic stellate cells. Front Biosci 2002; 7: d1720-d1726.
42. Eng FJ, Friedman SL. Transcriptional regulation in hepatic stellate cells. Semin Liver Dis 2001; 21: 385-395.
43. Mann J, Mann DA. Transcriptional regulation of hepatic stellate cells. Adv Drug Deliv Rev 2009; 61: 497-512.
44. Wang J, Leclercq I, Brymora JM, Xu N, Ramezani-Moghadam M, London RM, et al. Kupffer cells mediate leptin-induced liver fibrosis. Gastroenterology 2009; 137: 713-723.
45. Lee J, Decker N, Chatterjee S, Yao J, Friedman S, Shah V. Mechanisms of nitric oxide interplay with Rho GTPase family members in modulation of actin membrane dynamics in pericytes and fibroblasts. Am J Pathol 2005; 166: 1861-1870.
46. Langer DA, Das A, Semela D, Kang-Decker N, Hendrickson H, Bronk SF, et al. Nitric oxide promotes caspase independent hepatic stellate cell apoptosis through generation of reactive oxygen species. Hepatology 2008; 47: 1983-1993.
47. Decker NK, Abdelmoneim SS, Yaqoob U, Hendrickson H, Hormes J, Bentley M, et al. Nitric oxide regulates tumor cell cross-talk with stromal cells in the tumor microenvironment of the liver. Am J Pathol 2008; 173: 1002-1012.
48. Nam JS, Terabe M, Mamura M, Kang MJ, Chae H, Stuelten C, et al. An anti-transforming growth factor beta antibody suppresses metastasis via cooperative effects on multiple cell compartments. Cancer Res 2008; 68: 3835-3843.
49. Ganapathy V, Ge R, Grazioli A, Xie W, Banach-Petrosky W, Kang Y, et al. Targeting the transforming growth factor-beta pathway inhibits human basal-like breast cancer metastasis. Mol Cancer 2010; 9: 122.
50. Siegel PM, Shu W, Cardiff RD, Muller WJ, Massague J. Transforming growth factor beta signaling impairs Neu-induced mammary tumorigenesis while promoting pulmonary metastasis. Proc Natl Acad Sci U S A 2003; 100: 8430-8435.
51. Yang YA, Dukhanina O, Tang B, Mamura M, Letterio JJ, MacGregor J, et al. Lifetime exposure to a soluble TGF-beta antagonist protects mice against metastasis without adverse side effects. J Clin Invest 2002; 109: 1607-1615.
52. Korpal M, Kang Y. Targeting the transforming growth factor-beta signalling pathway in metastatic cancer. Eur J Cancer; 46: 1232-1240.
53. Tugues S, Fernandez-Varo G, Muñoz-Luque J, Ros J, Arroyo V, Rodés J, et al. Antiangiogenic treatment with sunitinib ameliorates inflammatory infiltrate, fibrosis, and portal pressure in cirrhotic rats. Hepatology 2007; 46: 1919-1926.
54. Yoshiji H, Noguchi R, Kuriyama S, Ikenaka Y, Yoshii J, Yanase K, et al. Imatinib mesylate (STI-571) attenuates liver fibrosis development in rats. Am J Physiol Gastrointest Liver Physiol 2005; 288: G907-G913.
55. Wang Y, Gao J, Zhang D, Zhang J, Ma J, Jiang H. New insights into the antifibrotic effects of sorafenib on hepatic stellate cells and liver fibrosis. J Hepatol; 53: 132-144.
56. Cazac BB, Roes J. TGF-beta receptor controls B cell responsiveness and induction of IgA in vivo. Immunity 2000; 13: 443-451.
57. Ostman A. PDGF receptors-mediators of autocrine tumor growth and regulators of tumor vasculature and stroma. Cytokine Growth Factor Rev 2004; 15: 275-286.